Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer

• Xiang Ling,
• Wenjie Wu,
• Li Yan,
• Leslie Curtin,
• Melanie M. Farrauto,
• Sandra Sexton,
• Anmbreen Jamroze,
• Changjun Yu,
• Christos Fountzilas,
• Dean G. Tang,
• Fengzhi Li

Affiliations

Xiang Ling

Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Canget BioTekpharma LLC, Buffalo, New York, 14203, USA

Wenjie Wu

Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Canget BioTekpharma LLC, Buffalo, New York, 14203, USA

Li Yan

Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo, New York, 14263, USA

Leslie Curtin

Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA

Melanie M. Farrauto

Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA

Sandra Sexton

Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA

Anmbreen Jamroze

Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA

Changjun Yu

California Institute of Technology, Pasadena, CA, 91125, USA

Christos Fountzilas

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA

Dean G. Tang

Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA

Fengzhi Li

Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Corresponding author.